BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 14671631)

  • 1. CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review.
    Béné MC; Castoldi G; Knapp W; Rigolin GM; Escribano L; Lemez P; Ludwig WD; Matutes E; Orfao A; Lanza F; van't Veer M;
    Leukemia; 2004 Mar; 18(3):394-400. PubMed ID: 14671631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and functional role of urokinase-type plasminogen activator receptor in normal and acute leukaemic cells.
    Lanza F; Castoldi GL; Castagnari B; Todd RF; Moretti S; Spisani S; Latorraca A; Focarile E; Roberti MG; Traniello S
    Br J Haematol; 1998 Oct; 103(1):110-23. PubMed ID: 9792297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urokinase plasminogen activator receptor (uPAR; CD87) expression on monocytic cells and T cells is modulated by HIV-1 infection.
    Speth C; Pichler I; Stöckl G; Mair M; Dierich MP
    Immunobiology; 1998 Jul; 199(1):152-62. PubMed ID: 9717675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urokinase-type plasminogen activator receptor reversibly dissociates from complement receptor type 3 (alpha M beta 2' CD11b/CD18) during neutrophil polarization.
    Kindzelskii AL; Laska ZO; Todd RF; Petty HR
    J Immunol; 1996 Jan; 156(1):297-309. PubMed ID: 8598477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis.
    Graf M; Reif S; Hecht K; Pelka-Fleischer R; Pfister K; Schmetzer H
    Am J Hematol; 2005 May; 79(1):26-35. PubMed ID: 15849776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
    Plesner T; Behrendt N; Ploug M
    Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients.
    Rigolin GM; Tieghi A; Ciccone M; Bragotti LZ; Cavazzini F; Della Porta M; Castagnari B; Carroccia R; Guerra G; Cuneo A; Castoldi G
    Br J Haematol; 2003 Mar; 120(6):953-9. PubMed ID: 12648064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and functional role of urokinase-type plasminogen activator receptor (UPA-R; CD87) in normal and acute leukemia cells.
    Castagnari B; Moretti S; Latorraca A; Spisani S; Traniello S; Castoldi GL; Lanza F
    Eur J Histochem; 1997; 41 Suppl 2():109-10. PubMed ID: 9859806
    [No Abstract]   [Full Text] [Related]  

  • 9. Hemostatic balance on the surface of leukemic cells: the role of tissue factor and urokinase plasminogen activator receptor.
    Nadir Y; Katz T; Sarig G; Hoffman R; Oliven A; Rowe JM; Brenner B
    Haematologica; 2005 Nov; 90(11):1549-56. PubMed ID: 16266903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and localization of the urokinase-type plasminogen activator receptor (uPAR) in the human placenta.
    Nishida Y; Hayashi Y; Imai Y; Itoh H
    Kobe J Med Sci; 1998 Feb; 44(1):31-43. PubMed ID: 9846056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The urokinase-receptor (CD87) is expressed in cells of the megakaryoblastic lineage.
    Wohn KD; Kanse SM; Deutsch V; Schmidt T; Eldor A; Preissner KT
    Thromb Haemost; 1997 Mar; 77(3):540-7. PubMed ID: 9066008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
    Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urokinase plasminogen activator receptor (CD87): something old, something new.
    Ge Y; Elghetany MT
    Lab Hematol; 2003; 9(2):67-71. PubMed ID: 12828301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
    Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on functional and structural role of urokinase receptor and other components of the plasminogen activation system in malignancy.
    Weidle UH; Wöllisch E; Rønne E; Ploug M; Behrendt N; de Vries TJ; Quax PH; Verheijen JH; van Muijen GN; Ruiter DJ
    Ann Biol Clin (Paris); 1994; 52(11):775-82. PubMed ID: 7747886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression.
    Wilhelm OG; Wilhelm S; Escott GM; Lutz V; Magdolen V; Schmitt M; Rifkin DB; Wilson EL; Graeff H; Brunner G
    J Cell Physiol; 1999 Aug; 180(2):225-35. PubMed ID: 10395292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between urokinase-type plasminogen receptor, interleukin-8 gene expression and clinicopathological features in gastric cancer.
    Lee KH; Bae SH; Lee JL; Hyun MS; Kim SH; Song SK; Kim HS
    Oncology; 2004; 66(3):210-7. PubMed ID: 15218312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and cellular localization of the urokinase-type plasminogen activator and its receptor in human hepatocellular carcinoma.
    Dubuisson L; Monvoisin A; Nielsen BS; Le Bail B; Bioulac-Sage P; Rosenbaum J
    J Pathol; 2000 Feb; 190(2):190-5. PubMed ID: 10657018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct patterns of urokinase receptor (uPAR) expression by leukemic cells and peripheral blood cells.
    Jardí M; Inglés-Esteve J; Burgal M; Azqueta C; Velasco F; López-Pedrera C; Miles LA; Félez J
    Thromb Haemost; 1996 Dec; 76(6):1009-19. PubMed ID: 8972026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
    Meijer-van Gelder ME; Look MP; Peters HA; Schmitt M; Brünner N; Harbeck N; Klijn JG; Foekens JA
    Cancer Res; 2004 Jul; 64(13):4563-8. PubMed ID: 15231667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.